



ADVIK LABORATORIES LIMITED

Regd. Off. : 138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2017

CIN : L74899HR1994PLC038300

Rs. In Lacs

S.No	Particulars	Quarter Ended			Year Ended	
		31-Mar-17	31-Dec-16	31-03-2016	31-Mar-17	31-Mar-16
		Audited	Un-audited	Audited	Audited	Audited
I	Revenue from operations	33.42	91.73	12.44	226.86	26.54
II	Other income	19.50	10.06	71.13	59.90	109.28
III	Total Revenue (I + II)	52.92	101.79	83.57	286.76	135.82
IV	Expenses:					
	Cost of materials consumed	304.61	85.93	19.96	461.70	42.78
	Purchases of Stock-in-Trade	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(25.14)	(14.81)	10.05	362.06	(1.43)
	Employee benefits expense	22.04	19.32	16.69	77.75	78.08
	Finance costs	-	0.04	(19.03)	0.09	8.22
	Depreciation and amortization expense	14.75	14.77	15.56	59.03	62.49
	Other expenses	19.87	19.88	20.86	69.12	65.35
	Total expenses	336.13	125.13	64.09	1,029.75	255.49
V	Profit before exceptional and extraordinary items and tax (III - IV)	(283.21)	(23.34)	19.48	(742.99)	(119.67)
VI	Exceptional items					
VII	Profit before extraordinary items and tax (V - VI)	(283.21)	(23.34)	19.48	(742.99)	(119.67)
VIII	Extraordinary items					
IX	Profit before tax (VII- VIII)	(283.21)	(23.34)	19.48	(742.99)	(119.67)
X	Tax expense:					
	(1) Current tax					
	(2) Deferred tax	-	-	-	(5.65)	(0.66)
XI	Profit (Loss) for the period from continuing operations (VII-VIII)	(283.21)	(23.34)	19.48	(737.34)	(119.01)
XII	Profit/(loss) from discontinuing operations					
XIII	Tax expense of discontinuing operations					
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(283.21)	(23.34)	19.48	(737.34)	(119.01)
XVI	Earnings per equity share:					
	(1) Basic	(1.48)	(0.12)	0.10	(3.86)	(0.62)
	(2) Diluted	(1.48)	(0.12)	0.10	(3.86)	(0.62)

Cont.....page 2




STATEMENT OF ASSETS AND LIABILITIES		
Particulars	As at 31st March 2017	As at 31st March 2016
I. EQUITY AND LIABILITIES		
(1) Shareholders' funds		
(a) Share capital	1,911.14	1,911.14
(b) Reserves and surplus	(750.19)	(12.85)
(c) Money received against share warrants	-	-
(2) Share application money pending allotment		
(3) Non-current liabilities		
(a) Long-term borrowings	-	97.60
(b) Deferred tax liabilities (Net)	92.34	98.00
(c) Other Long term liabilities	-	-
(d) Long-term provisions	12.78	18.42
(4) Current liabilities		
(a) Short-term borrowings	289.52	289.52
(b) Trade payables	36.30	64.42
(c) Other current liabilities	501.17	391.09
(d) Short-term provisions	-	-
TOTAL	2,093.06	2,857.34
II. ASSETS		
Non-current assets		
(1) (a) Fixed assets		
(i) Tangible assets	705.87	763.51
(ii) Intangible assets	-	-
(iii) Capital work-in-progress	551.01	615.20
(iv) Intangible assets under development	-	-
(b) Non-current investments	92.30	92.30
(c) Deferred tax assets (net)	-	-
(d) Long-term loans and advances	-	-
(e) Other non-current assets	-	-
(2) Current assets		
(a) Current investments	-	-
(b) Inventories	113.27	753.10
(c) Trade receivables	414.33	427.19
(d) Cash and cash equivalents	5.53	3.12
(e) Short-term loans and advances	210.29	202.52
(f) Other current assets	0.46	0.40
TOTAL	2,093.06	2,857.34

Notes :

- 1 The Above results for the quarter and year ended March 31, 2017 has been reviewed by the Audit Commiottee and thereafter approved by the Board of Directrs at their meeting held on 30th May, 2017.
- 2 The results for the year ended 31st March, 2017 have been audited by the Auditor's of the Company
- 3 The Figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year.
- 4 The Company is operating only in the Pharmaceuticals Segment, hence Reporting as defined in AS-17 is not applicable.
- 5 Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figure.
- 6 The statement of Audited financial statements for the year ended 31st March, 2017 has been prepared following the same accounting policies as ended 31st March, 2016 were followed in the annual financial statements for the year
- 7 During the quarter under review, stocks worth Rs. 256.46 lacs got expired, thereby materially increasing the total loss of the company, from Rs. 26.75 lacs to Rs. 283.21 lacs.

For and on behalf of Board of Directors of
Advik Laboratories Ltd.


(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423



Place: New Delhi
Date : 30.05.2017